MX2009013781A - Inhibidores de cinasa de proteina y metodos para el uso de los mismos. - Google Patents
Inhibidores de cinasa de proteina y metodos para el uso de los mismos.Info
- Publication number
- MX2009013781A MX2009013781A MX2009013781A MX2009013781A MX2009013781A MX 2009013781 A MX2009013781 A MX 2009013781A MX 2009013781 A MX2009013781 A MX 2009013781A MX 2009013781 A MX2009013781 A MX 2009013781A MX 2009013781 A MX2009013781 A MX 2009013781A
- Authority
- MX
- Mexico
- Prior art keywords
- raf
- methods
- compounds
- protein kinase
- kinase inhibitors
- Prior art date
Links
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 title abstract 2
- 239000003909 protein kinase inhibitor Substances 0.000 title abstract 2
- -1 EphB4 Proteins 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 230000002159 abnormal effect Effects 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- KKVYYGGCHJGEFJ-UHFFFAOYSA-N 1-n-(4-chlorophenyl)-6-methyl-5-n-[3-(7h-purin-6-yl)pyridin-2-yl]isoquinoline-1,5-diamine Chemical compound N=1C=CC2=C(NC=3C(=CC=CN=3)C=3C=4N=CNC=4N=CN=3)C(C)=CC=C2C=1NC1=CC=C(Cl)C=C1 KKVYYGGCHJGEFJ-UHFFFAOYSA-N 0.000 abstract 1
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 abstract 1
- 101150053778 CSF1R gene Proteins 0.000 abstract 1
- ZEOWTGPWHLSLOG-UHFFFAOYSA-N Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F Chemical compound Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F ZEOWTGPWHLSLOG-UHFFFAOYSA-N 0.000 abstract 1
- 101100503636 Danio rerio fyna gene Proteins 0.000 abstract 1
- 101100481408 Danio rerio tie2 gene Proteins 0.000 abstract 1
- 108010055334 EphB2 Receptor Proteins 0.000 abstract 1
- 102100030779 Ephrin type-B receptor 1 Human genes 0.000 abstract 1
- 102100031968 Ephrin type-B receptor 2 Human genes 0.000 abstract 1
- 102100031983 Ephrin type-B receptor 4 Human genes 0.000 abstract 1
- 101150018272 FYN gene Proteins 0.000 abstract 1
- 102100023593 Fibroblast growth factor receptor 1 Human genes 0.000 abstract 1
- 101710182386 Fibroblast growth factor receptor 1 Proteins 0.000 abstract 1
- 102100023600 Fibroblast growth factor receptor 2 Human genes 0.000 abstract 1
- 101710182389 Fibroblast growth factor receptor 2 Proteins 0.000 abstract 1
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 abstract 1
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 abstract 1
- 101001064150 Homo sapiens Ephrin type-B receptor 1 Proteins 0.000 abstract 1
- 101001051777 Homo sapiens Protein kinase C alpha type Proteins 0.000 abstract 1
- 101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 abstract 1
- 101000851018 Homo sapiens Vascular endothelial growth factor receptor 1 Proteins 0.000 abstract 1
- 101150028321 Lck gene Proteins 0.000 abstract 1
- 101150058160 Lyn gene Proteins 0.000 abstract 1
- 102100027754 Mast/stem cell growth factor receptor Kit Human genes 0.000 abstract 1
- 101100381978 Mus musculus Braf gene Proteins 0.000 abstract 1
- 101100335081 Mus musculus Flt3 gene Proteins 0.000 abstract 1
- 101100354317 Mus musculus Ptk6 gene Proteins 0.000 abstract 1
- 101100481410 Mus musculus Tek gene Proteins 0.000 abstract 1
- 101150056950 Ntrk2 gene Proteins 0.000 abstract 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 102000001393 Platelet-Derived Growth Factor alpha Receptor Human genes 0.000 abstract 1
- 108010068588 Platelet-Derived Growth Factor alpha Receptor Proteins 0.000 abstract 1
- 102100024924 Protein kinase C alpha type Human genes 0.000 abstract 1
- 101150083487 SIK1 gene Proteins 0.000 abstract 1
- 101150001535 SRC gene Proteins 0.000 abstract 1
- 101150110875 Syk gene Proteins 0.000 abstract 1
- 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 abstract 1
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 abstract 1
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 101150060629 def gene Proteins 0.000 abstract 1
- 230000002074 deregulated effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La invención proporciona compuestos y composiciones farmacéuticas de los mismos, los cuales son útiles como inhibidores de la cinasa de proteína, y métodos para utilizar tales compuestos con el fin de tratar, aminorar, o prevenir una condición asociada con una actividad anormal o mal regulada de la cinasa. En algunas modalidades, la invención proporciona métodos para utilizar estos compuestos con el fin de tratar, aminorar, o prevenir enfermedades o trastornos que involucren una activación anormal de las cinasas Alk, AbI, Aurora-A, B-Raf, C-Raf, Bcr-Abl, BRK, Blk, Bmx, BTK, C-Kit, C-Raf, C-Src, EphB1, EphB2, EphB4, FGFR1, FGFR2, FGFR3, FLT1, Fms, Flt3, Fyn, FRK3, JAK2, KDR, Lck, Lyn, PDGFRa, PDGFRß, PKCa, p38, Src, SIK, Syk, Tie2 y TrkB.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94541007P | 2007-06-21 | 2007-06-21 | |
| PCT/US2008/067290 WO2008157575A1 (en) | 2007-06-21 | 2008-06-18 | Protein kinase inhibitors and methods for using thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2009013781A true MX2009013781A (es) | 2010-02-01 |
Family
ID=39682516
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2009013781A MX2009013781A (es) | 2007-06-21 | 2008-06-18 | Inhibidores de cinasa de proteina y metodos para el uso de los mismos. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20110053932A1 (es) |
| EP (1) | EP2170842A1 (es) |
| JP (1) | JP2010530438A (es) |
| KR (1) | KR20100035635A (es) |
| CN (1) | CN101687821A (es) |
| AU (1) | AU2008265843B2 (es) |
| BR (1) | BRPI0813216A2 (es) |
| CA (1) | CA2691100A1 (es) |
| EA (1) | EA201000003A1 (es) |
| MX (1) | MX2009013781A (es) |
| WO (1) | WO2008157575A1 (es) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007345526B2 (en) | 2007-02-01 | 2013-02-28 | Resverlogix Corp. | Compounds for the prevention and treatment of cardiovascular diseases |
| JP2011513332A (ja) * | 2008-02-29 | 2011-04-28 | アレイ バイオファーマ、インコーポレイテッド | 癌の治療のためのｒａｆ阻害剤としてのｎ−（６−アミノピリジン−３−イル）−３−（スルホンアミド）ベンズアミド誘導体 |
| WO2009111277A1 (en) * | 2008-02-29 | 2009-09-11 | Array Biopharma Inc. | Imdizo [4. 5-b] pyridine derivatives used as raf inhibitors |
| CL2009000447A1 (es) * | 2008-02-29 | 2010-01-04 | Array Biopharma Inc Y Genentech Inc | Compuestos derivados de (1h-pirrolo{2,3-b}piridin-5-il)-sulfonamido-benzamida sustituida; procedimiento de preparacion; composicion farmaceutica; y su uso en el tratamiento del cancer, a travez de la inhibicion de raf. |
| TW200940539A (en) * | 2008-02-29 | 2009-10-01 | Array Biopharma Inc | RAF inhibitor compounds and methods of use thereof |
| US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
| EA029131B1 (ru) | 2008-05-21 | 2018-02-28 | Ариад Фармасьютикалз, Инк. | Фосфорсодержащие производные в качестве ингибиторов киназы |
| MX392179B (es) | 2009-03-18 | 2025-03-21 | Resverlogix Corp | Nuevos agentes anti-inflamatorios. |
| TR201818390T4 (tr) | 2009-04-22 | 2019-01-21 | Resverlogix Corp | Yeni̇ anti̇-i̇nflamatuvar ajanlar |
| EP2519517B1 (en) * | 2009-12-29 | 2015-03-25 | Dana-Farber Cancer Institute, Inc. | Type ii raf kinase inhibitors |
| US8669256B2 (en) | 2010-05-28 | 2014-03-11 | Merck Sharp & Dohme B.V. | Substituted thieno[2,3-b]pyrazine compounds as modulators of B-Raf kinase activity |
| WO2012037155A2 (en) * | 2010-09-13 | 2012-03-22 | Gtx, Inc. | Tyrosine kinase inhibitors |
| CA2832504C (en) | 2011-05-04 | 2019-10-01 | Ariad Pharmaceuticals, Inc. | Compounds for inhibiting cell proliferation in egfr-driven cancers |
| KR102247818B1 (ko) | 2011-08-10 | 2021-05-04 | 삼성전자 주식회사 | 이동통신 시스템에서 복수의 캐리어를 이용해서 데이터를 전송하는 방법 및 장치 |
| KR101967721B1 (ko) | 2011-08-10 | 2019-04-10 | 삼성전자 주식회사 | 무선 통신 시스템에서 확장 접속 차단 적용 방법 및 장치 |
| EP3429307B1 (en) | 2011-08-10 | 2022-06-15 | Samsung Electronics Co., Ltd. | Method and apparatus for transmitting data using a multi-carrier in a mobile communication system |
| US10321419B2 (en) | 2011-08-10 | 2019-06-11 | Samsung Electronics Co., Ltd. | Method and apparatus for transmitting data using a multi-carrier in a mobile communication system |
| CN103858489A (zh) | 2011-10-05 | 2014-06-11 | 三星电子株式会社 | 在移动通信系统中选择相邻小区的方法和装置 |
| CN103875285B (zh) | 2011-10-05 | 2018-05-08 | 三星电子株式会社 | 用于在无线通信系统中的异构网络中重新选择小区的方法和装置 |
| EP3349396B1 (en) | 2011-10-10 | 2021-05-05 | Samsung Electronics Co., Ltd. | Method and device for performing random access in a secondary cell |
| AU2013204563B2 (en) | 2012-05-05 | 2016-05-19 | Takeda Pharmaceutical Company Limited | Compounds for inhibiting cell proliferation in EGFR-driven cancers |
| CN104884427B (zh) * | 2012-10-15 | 2016-09-07 | 雷斯韦洛吉克斯公司 | 可用于合成苯甲酰胺化合物的化合物 |
| WO2014138364A2 (en) | 2013-03-06 | 2014-09-12 | Genentech, Inc. | Methods of treating and preventing cancer drug resistance |
| US9611283B1 (en) | 2013-04-10 | 2017-04-04 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in ALK-driven cancers |
| US20230190750A1 (en) | 2014-06-13 | 2023-06-22 | Genentech, Inc. | Methods of treating and preventing cancer drug resistance |
| WO2016073889A1 (en) | 2014-11-06 | 2016-05-12 | Lysosomal Therapeutics Inc. | Substituted imidazo[1,5-a]pyrimidines and their use in the treatment of medical disorders |
| AU2015342883B2 (en) | 2014-11-06 | 2020-07-02 | Bial - R&D Investments, S.A. | Substituted pyrrolo(1,2-a)pyrimidines and their use in the treatment of medical disorders |
| IL252053B2 (en) | 2014-11-06 | 2024-04-01 | Lysosomal Therapeutics Inc | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS |
| KR102662814B1 (ko) | 2015-03-13 | 2024-05-03 | 리스버로직스 코퍼레이션 | 보체 관련 질환을 치료하기 위한 조성물 및 치료 방법 |
| WO2017066193A1 (en) | 2015-10-15 | 2017-04-20 | Princeton Drug Discovery, Llc | Novel inhibitors of protein kinases |
| CA3020305A1 (en) | 2016-04-06 | 2017-10-12 | Lysosomal Therapeutics Inc. | Imidazo [1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders |
| US11124516B2 (en) | 2016-04-06 | 2021-09-21 | BIAL-BioTech Investments, Inc. | Pyrrolo[1,2-A]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders |
| KR20180133461A (ko) | 2016-04-06 | 2018-12-14 | 리소소말 테라퓨틱스 인크. | 피라졸로[1,5-a]피리미디닐 카르복스아미드 화합물 및 의학적 장애의 치료에서의 그의 용도 |
| US20190389865A1 (en) * | 2016-05-05 | 2019-12-26 | Lysosomal Therapeutics Inc. | SUBSTITUTED PYRROLO[1,2-a]TRIAZINES AND RELATED COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS |
| MX389579B (es) | 2016-05-05 | 2025-03-20 | Bial R&D Invest S A | IMIDAZO[1,2-b]PIRIDAZINAS SUSTITUIDAS, IMIDAZO[1,5-b]PIRIDAZINAS SUSTITUIDAS, COMPUESTOS RELACIONADOS Y SU USO EN EL TRATAMIENTO DE TRASTORNOS MÉDICOS |
| US11345698B2 (en) | 2016-05-05 | 2022-05-31 | Bial—R&D Investments, S.A. | Substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-a]pyrazines, related compounds, and their use in the treatment of medical disorders |
| CA3124422A1 (en) | 2018-12-28 | 2020-07-02 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 and uses thereof |
| CN112979615B (zh) * | 2019-12-17 | 2024-08-09 | 上海医药集团股份有限公司 | 一种喹唑啉脲类化合物、其制备方法、制备中间体、药物组合物及应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE339406T1 (de) * | 1999-09-23 | 2006-10-15 | Astrazeneca Ab | Chinazoline verbindungen als heilmittel |
| RU2283311C2 (ru) * | 2000-06-28 | 2006-09-10 | Астразенека Аб | Замещенные производные хиназолина и их применение в качестве ингибиторов |
| WO2004024710A1 (en) * | 2002-09-13 | 2004-03-25 | Glaxo Group Limited | Urea compounds active as vanilloid receptor antagonists for the treatment of pain |
| EP1748991A1 (en) * | 2004-04-28 | 2007-02-07 | Arrow Therapeutics Limited | Morpholinylanilinoquinazo- line derivatives for use as antiviral agents |
-
2008
- 2008-06-18 AU AU2008265843A patent/AU2008265843B2/en not_active Expired - Fee Related
- 2008-06-18 CN CN200880021088A patent/CN101687821A/zh active Pending
- 2008-06-18 EA EA201000003A patent/EA201000003A1/ru unknown
- 2008-06-18 MX MX2009013781A patent/MX2009013781A/es active IP Right Grant
- 2008-06-18 KR KR1020097026460A patent/KR20100035635A/ko not_active Withdrawn
- 2008-06-18 WO PCT/US2008/067290 patent/WO2008157575A1/en not_active Ceased
- 2008-06-18 EP EP08771318A patent/EP2170842A1/en not_active Withdrawn
- 2008-06-18 JP JP2010513369A patent/JP2010530438A/ja active Pending
- 2008-06-18 BR BRPI0813216-0A2A patent/BRPI0813216A2/pt not_active IP Right Cessation
- 2008-06-18 US US12/665,894 patent/US20110053932A1/en not_active Abandoned
- 2008-06-18 CA CA2691100A patent/CA2691100A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2170842A1 (en) | 2010-04-07 |
| BRPI0813216A2 (pt) | 2014-12-23 |
| CN101687821A (zh) | 2010-03-31 |
| US20110053932A1 (en) | 2011-03-03 |
| AU2008265843A1 (en) | 2008-12-24 |
| JP2010530438A (ja) | 2010-09-09 |
| AU2008265843B2 (en) | 2012-02-09 |
| KR20100035635A (ko) | 2010-04-05 |
| WO2008157575A1 (en) | 2008-12-24 |
| EA201000003A1 (ru) | 2010-06-30 |
| CA2691100A1 (en) | 2008-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2009013781A (es) | Inhibidores de cinasa de proteina y metodos para el uso de los mismos. | |
| MX2009013782A (es) | Inhibidores de cinasa de proteina y metodos para el uso de los mismos. | |
| MX2008002165A (es) | Compuestos y composiciones como inhibidores de la proteina cinasa. | |
| MX2008001969A (es) | Compuestos y composiciones como inhibidores de proteina cinasa. | |
| ATE499374T1 (de) | Verbindungen und zusammensetzungen als proteinkinase-hemmer | |
| EA201000325A1 (ru) | Производные 2-гетероариламинопиримидина в качестве ингибиторов киназ | |
| DE602006014540D1 (en) | Pyrrolopyridinderivate als proteinkinaseinhibitoren | |
| MX2009004141A (es) | Composiciones y metodos para modular receptores de c-kit y pdgfr. | |
| WO2006124731A3 (en) | Compounds and compositions as protein kinase inhibitors | |
| TW200726766A (en) | Compounds and compositions as protein kinase inhibitors | |
| PH12014500372A1 (en) | Compounds and compositions as c-kit kinase inhibitors | |
| TN2014000061A1 (en) | COMPOUNDS AND COMPOSITIONS AS c-KIT KINASE INHIBITORS | |
| MX2009003456A (es) | Compuestos y composiciones como inhibidores de proteina cinasa. | |
| TNSN06406A1 (en) | Compounds and compositions as protein kinase inhibitors | |
| TW200637547A (en) | Compounds and compositions as protein kinase inhibitors | |
| TNSN06053A1 (en) | 6-substituted anilino purines as rtk inhibitors | |
| MX2009003649A (es) | Inhibidores de cinasa de proteina y metodos para utilizarlos. | |
| PH12016500575A1 (en) | Inhibitors of bruton`s tyrosine kinase | |
| TNSN07176A1 (en) | Compounds and compositions as protein kinase inhibitors | |
| MY167575A (en) | Heterocyclic compounds and use thereof as modulators of type iii receptor tyrosine kinases | |
| EA201790995A1 (ru) | ЗАМЕЩЕННЫЕ ПИРАЗОЛО[1,5-a]ПИРИМИДИНЫ И ИХ ПРИМЕНЕНИЕ ПРИ ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ | |
| MX2017015574A (es) | Inhibidores de tirosina quinasa de bruton. | |
| MX2009009117A (es) | Derivados de pirimidin-2,4-diamina y su uso como inhibidores de la cinasa jak2. | |
| PT1940844E (pt) | Compostos e composições como inibidores de proteína-quinase | |
| GB201206908D0 (en) | Therapeutic compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HH | Correction or change in general | ||
| FG | Grant or registration |